Common use of Development After a Withdrawal by ADCT Clause in Contracts

Development After a Withdrawal by ADCT. If ADCT elects a Withdrawal, then Genmab, if it elects to be the Continuing Party, shall be the sole developing Party and be solely responsible for executing and funding the Pre-Clinical Work Plan and Clinical Work Plan, as approved and modified by the JSC from time to time, until the completion of the Qualifying Phase I/II Clinical Trial. For clarity, the Continuing Party shall be responsible for the additional [**] payments (if any) and as set out in the amended section 6.4 and 100% of the milestone payment also as set out in the amended section 6.4. The member of the JSC appointed by Genmab shall have the casting vote. Genmab shall provide to the JSC a report of the progress and work performed under the Pre- Clinical Work Plan, if applicable, and during the Clinical Phase of the Development every [**] months, the first report being due [**] months after ADCT’s Withdrawal. [**] per calendar year, Genmab shall provide ADCT with a written report summarizing Genmab’s significant activities performed and planned related to research and Development of the ADC and status of clinical trials. Such reports shall be deemed Genmab’s Confidential Information for the purposes of Article 11. If ADCT elects a Withdrawal prior to filing of an IND, and Genmab elects to be the Continuing Party the provisions of Articles 3 and 5 of this Agreement shall not be applicable. Certain confidential information contained in this document, marked by [**], has been omitted because ADC Therapeutics SA (ADCT) has determined that the information (i) is not material and (ii) would likely cause competitive harm to ADC Therapeutics SA (ADCT) if publicly disclosed. Save as set forth in this Amendment all other terms of the Agreement remain valid and unchanged. The Parties have caused this Amendment to be executed by their duly authorized representatives: Genmab A/S [**] [**] [**] ADC Therapeutics Sarl Xxx Xxxxx-Xxxxxx 0 Xxxxxxxx, 0000 Xxxxxxxxxxx Signature: /s/ [**] Signature: /s/ Xxxxxxx Xxxxx Print Name: [**] Print Name: Xxxxxxx Xxxxx Title: [**] Title: CEO Certain confidential information contained in this document, marked by [**], has been omitted because ADC Therapeutics SA (ADCT) has determined that the information (i) is not material and (ii) would likely cause competitive harm to ADC Therapeutics SA (ADCT) if publicly disclosed.

Development After a Withdrawal by ADCT. If ADCT elects a Withdrawal, then Genmab, if it elects to be the Continuing Party, shall be the sole developing Party and be solely responsible for executing and funding the Pre-Clinical Work Plan and Clinical Work Plan, as approved and modified by the JSC from time to time, until the completion of the Qualifying Phase I/II Clinical Trial. For clarity, the Continuing Party shall be responsible for the additional [**] payments (if any) and as set out in the amended section 6.4 and 100% of the milestone payment also as set out in the amended section 6.4. The member of the JSC appointed by Genmab shall have the casting vote. Genmab shall provide to the JSC a report of the progress and work performed under the Pre- Pre-Clinical Work Plan, if applicable, and during the Clinical Phase of the Development every [**] months, the first report being due [**] months after ADCT’s Withdrawal. [**] per calendar year, Genmab shall provide ADCT with a written report summarizing Genmab’s significant activities performed and planned related to research and Development of the ADC and status of clinical trials. Such reports shall be deemed Genmab’s Confidential Information for the purposes of Article 11. If ADCT elects a Withdrawal prior to filing of an IND, and Genmab elects to be the Continuing Party the provisions of Articles 3 and 5 of this Agreement shall not be applicable. Certain confidential information contained in this document, marked by [**], has been omitted because ADC Therapeutics SA (ADCT) has determined that the information (i) is not material and (ii) would likely cause competitive harm to ADC Therapeutics SA (ADCT) if publicly disclosed. Save as set forth in this Amendment all other terms of the Agreement remain valid and unchanged. The Parties have caused this Amendment to be executed by their duly authorized representatives: Genmab A/S [**] [**] [**] ADC Therapeutics Sarl Xxx Xxxxx-Xxxxxx 0 Xxxxxxxx, 0000 Xxxxxxxxxxx Signature: /s/ [**] Signature: /s/ Xxxxxxx Xxxxx Print Name: [**] Print Name: Xxxxxxx Xxxxx Title: [**] Title: CEO Certain confidential information contained in this document, marked by [**], has been omitted because ADC Therapeutics SA (ADCT) has determined that the information (i) is not material and (ii) would likely cause competitive harm to ADC Therapeutics SA (ADCT) if publicly disclosed.